ArticleACS pharmacology & translational science2026
A Minimally Invasive, Subcutaneous Biosensor Reliably Estimates Plasma Methotrexate Exposure and Quantifies Plasma-to-Tissue Transport Kinetics.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electrochemical aptamer-based (EAB) sensors enable high-frequency, real-time measurements of drug concentrations in situ in the body, offering a potential means of rendering therapeutic drug monitoring (TDM) as convenient, timely, and precise as the continuous glucose monitor has rendered the measurement of blood sugar. Fully realizing this vision, however, will require improved understanding of the relationship between drug concentrations in the interstitial fluid (ISF) and in the plasma, as the latter are the basis of nearly all clinical decision-making. Toward this end, here we have used an EAB sensor against the chemotherapeutic methotrexate, a drug that requires monitoring to optimize efficacy and minimize toxicity, to perform simultaneous, seconds-resolved concentration measurements in the plasma and subcutaneous ISF of live rats. Noncompartmental analysis reveals that, while body-mass-adjusted dose is a poor predictor of methotrexate exposure (as area under the curve) in either bodily compartment (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.